203 related articles for article (PubMed ID: 30381969)
1. The changing face of treatment for metastatic colorectal cancer.
Pfeiffer P; Köhne CH; Qvortrup C
Expert Rev Anticancer Ther; 2019 Jan; 19(1):61-70. PubMed ID: 30381969
[No Abstract] [Full Text] [Related]
2. Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials.
Matos I; Noguerido A; Ros J; Mulet N; Argilés G; Elez É; Tabernero J
Expert Opin Investig Drugs; 2019 May; 28(5):463-471. PubMed ID: 30905200
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy for metastatic colorectal cancer.
Price TJ; Tang M; Gibbs P; Haller DG; Peeters M; Arnold D; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M; Shapiro J
Expert Rev Anticancer Ther; 2018 Oct; 18(10):991-1006. PubMed ID: 30019590
[TBL] [Abstract][Full Text] [Related]
4. Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.
Lau DK; Burge M; Roy A; Chau I; Haller DG; Shapiro JD; Peeters M; Pavlakis N; Karapetis CS; Tebbutt NC; Segelov E; Price TJ
Expert Rev Anticancer Ther; 2020 Apr; 20(4):251-270. PubMed ID: 32186929
[No Abstract] [Full Text] [Related]
5. Metastatic colorectal cancer- third line therapy and beyond.
Foo T; Roy A; Karapetis C; Townsend A; Price T
Expert Rev Anticancer Ther; 2024 May; 24(5):219-227. PubMed ID: 38526540
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data.
Hansen TF; Qvortrup C; Pfeiffer P
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33804554
[TBL] [Abstract][Full Text] [Related]
7. Palliative treatment of unresectable metastatic colorectal cancer.
Fornaro L; Masi G; Loupakis F; Vasile E; Falcone A
Expert Opin Pharmacother; 2010 Jan; 11(1):63-77. PubMed ID: 20001430
[TBL] [Abstract][Full Text] [Related]
8. The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer.
Martinez-Perez J; Riesco-Martinez MC; Garcia-Carbonero R
Expert Opin Drug Saf; 2018 Jun; 17(6):643-650. PubMed ID: 29745737
[TBL] [Abstract][Full Text] [Related]
9. The safety of ramucirumab for the treatment of colorectal cancer.
Noguerido A; Mulet-Margalef N; Matos I; Ros J; Argilés G; Élez E; Tabernero J
Expert Opin Drug Saf; 2018 Sep; 17(9):945-951. PubMed ID: 30073902
[TBL] [Abstract][Full Text] [Related]
10. Options for Second-Line Treatment in Metastatic Colorectal Cancer.
Lee JJ; Sun W
Clin Adv Hematol Oncol; 2016 Jan; 14(1):46-54. PubMed ID: 27057668
[TBL] [Abstract][Full Text] [Related]
11. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches.
Atreya CE; Yaeger R; Chu E
Am Soc Clin Oncol Educ Book; 2017; 37():246-256. PubMed ID: 28561718
[TBL] [Abstract][Full Text] [Related]
12. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
Marques RP; Duarte GS; Sterrantino C; Pais HL; Quintela A; Martins AP; Costa J
Crit Rev Oncol Hematol; 2017 Oct; 118():54-62. PubMed ID: 28917269
[TBL] [Abstract][Full Text] [Related]
13. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.
Martini G; Troiani T; Cardone C; Vitiello P; Sforza V; Ciardiello D; Napolitano S; Della Corte CM; Morgillo F; Raucci A; Cuomo A; Selvaggi F; Ciardiello F; Martinelli E
World J Gastroenterol; 2017 Jul; 23(26):4675-4688. PubMed ID: 28765689
[TBL] [Abstract][Full Text] [Related]
14. Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.
Hanna DL; Lenz HJ
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1091-108. PubMed ID: 27031164
[TBL] [Abstract][Full Text] [Related]
15. Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement.
Yalcin S; Trad D; Kader YA; Halawani H; Demir OG; Mall R; Meshcheryakov A; Nasr F; Nosworthy A; Osinsky D; Tumanova A; Turhal S; Tejpar S; Köhne CH
Future Oncol; 2014 Dec; 10(16):2643-57. PubMed ID: 25531050
[TBL] [Abstract][Full Text] [Related]
16. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
Chung C; Pherwani N
Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.
Song X; Zhao Z; Barber B; Gregory C; Wang PF; Long SR
Curr Med Res Opin; 2011 Jan; 27(1):123-30. PubMed ID: 21128878
[TBL] [Abstract][Full Text] [Related]
18. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
Lee JJ; Chu E
Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.
Stintzing S; Stremitzer S; Sebio A; Lenz HJ
Hematol Oncol Clin North Am; 2015 Feb; 29(1):43-60. PubMed ID: 25475572
[TBL] [Abstract][Full Text] [Related]
20. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.
Lee YC; Michael M; Zalcberg JR
Expert Opin Investig Drugs; 2015; 24(10):1307-20. PubMed ID: 26212373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
